Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human umbilical cord mesenchymal stem cells (Shandong Qilu Cell Therapy)
- Development stage
- Unknown
- Lead developer
- Shandong Qilu Stem Cell Engineering
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Human umbilical cord mesenchymal stem cells (hUC-MSCs) developed by Shandong Qilu Cell Therapy Engineering Technology Co., Ltd is an investigational cell therapy for the treatment of HIV-infected immune non-responders (INRs). These patients fail to achieve adequate CD4+ T cell recovery despite effective antiretroviral therapy (ART). hUC-MSCs are adult stem cells characterized by their potent immunomodulatory and regenerative properties. The therapy works by reducing chronic systemic immune overactivation and promoting the reconstitution of the immune system, specifically by increasing circulating naïve and central memory CD4+ T cell counts. It has been evaluated in Phase I and Phase II clinical trials (e.g., NCT04125329, NCT01213186) where it was administered via intravenous infusion in combination with standard antiviral therapy.
- Other names
- hUC-MSCshuman umbilical cord-derived mesenchymal stem cellsUmbilical Cord MSCs for HIV Immune Non-Responders
Beyond the preview
Go deeper on human umbilical cord mesenchymal stem cells (Shandong Qilu Cell Therapy).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human umbilical cord mesenchymal stem cells (Shandong Qilu Cell Therapy).